Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles

Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles

The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatme...

Full description

Bibliographic Details
Main Authors: Marcos Lorca, Cesar Morales-Verdejo, David Vásquez-Velásquez, Juan Andrades-Lagos, Javier Campanini-Salinas, Jorge Soto-Delgado, Gonzalo Recabarren-Gajardo, Jaime Mella
Format: Article
Language:English
Published: MDPI AG 2018-05-01
Series:Molecules
Subjects:
β3-adrenergic receptor
obesity
diabetes
overactive bladder
aryloxypropanolamines
mirabegron
vibegron
3D-QSAR
CoMFA
CoMSIA
Online Access:http://www.mdpi.com/1420-3049/23/5/1191

Internet

http://www.mdpi.com/1420-3049/23/5/1191

Similar Items